| This article needs to be updated. Please help update this article to reflect newly available information.(December 2025) |
Rindopepimut (CDX-110) is an injectablepeptidecancer vaccine[1] which targets a mutant protein calledEGFRvIII present in about 25% to 30% ofglioblastoma cases.[2]
The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIIIepitope[3]) conjugated to the non-specificimmunomodulatorkeyhole limpet hemocyanin (KLH).[4]
TheUS FDA granted itBreakthrough Therapy designation forglioblastoma in Feb 2015 meaning that it might be able to get approval sooner if it is effective.[5]
The phase II ACT III study reported encouraging results in June 2015.[1]
The ReACT clinical trial for glioblastoma reported encouraging results in 2015.[2]
In March 2016 the phase III ACT IV trial[6] was terminated because it did not increaseoverall survival.[7]
 | This article aboutvaccines orvaccination is astub. You can help Wikipedia byadding missing information. |